Baird analyst Brian Skorney lowered the firm’s price target on Biogen to $333 from $340 and keeps an Outperform rating on the shares. The firm said although somewhat expected given the sudden change of management’s tenor recently, the CRL for zuranolone still serves as a strike against management, given how optimistic they sounded on a program that investors have been ambivalent on.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BIIB:
- Sage sees cash and equivalentes enough to support operations into 2025
- Sage, Biogen receive CRL for zuranolone in major depressive disorder
- FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
- FDA approves Zurzuvae for postpartum depression
- Biogen trading halted, news pending